MedTrace Logo

Pharmacokinetics and Metabolism of Radiolabeled BMS-690514 in Healthy Male Subjects

NCT00578916 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 17

Last updated 2008-07-31

No results posted yet for this study

Summary

The purpose of this study is to determine how the human body processes and eliminates the drug (BMS-690514.

Conditions

Interventions

DRUG

EVRI (BMS-690514)

Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay

Sponsors & Collaborators

Principal Investigators

  • Bristol-Myers Squibb · Bristol-Myers Squibb

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00578916 on ClinicalTrials.gov